Abstract
Most humans are infected with influenza viruses by 3-4 years of age (1) and have high antibody titers against viral strains encountered early in life (2). Early childhood influenza exposures can leave lifelong ‘immunological imprints’ that affect how an individual responds to antigenically distinct viral strains later in life (3,4). H3N2 influenza viruses began circulating in humans in 1968 and have evolved substantially over the past 51 years (5). Therefore, an individual’s birth year largely predicts which specific type of H3N2 virus they first encountered in childhood. Here, we completed a large serological survey to elucidate the specificity of antibodies against contemporary H3N2 viruses in differently aged individuals who were likely primed with different H3N2 strains in childhood. We found that most humans who were first infected in childhood with H3N2 viral strains from the 1960s and 1970s possess non-neutralizing antibodies against contemporary 3c2.A H3N2 viruses. Most importantly, we found that 3c2.A H3N2 virus infections boost non-neutralizing H3N2 antibodies in middle-aged individuals, potentially leaving many of them in a perpetual state of 3c2.A H3N2 viral susceptibility.
Competing Interest Statement
S.E.H. has received consultancy fee from Sanofi Pasteur, Lumen, Novavax, and Merck for work unrelated to this report. A.S.M. has received consultancy fees from Sanofi Pasteur, Seqirus, and Novavax for work unrelated to this report. A.B. reports has received consultancy fees from GSK and Merck and grant support from Merck, Pfizer, and Janssen for work unrelated to this report. All other authors report no potential conflicts
Clinical Trial
de-identified samples used, not trial ID
Funding Statement
This work was supported by the National Institute of Allergy and Infectious Diseases (1R01AI113047, S.E.H.; 1R01AI108686, S.E.H.; 1R01AI097150, A.S.M.; CEIRS HHSN272201400005C, S.E.H., S.C., E.T.M., A.S.M. A.B., D.J.T.) and Center for Disease Control (U01IP000474, A.S.M.). Scott E. Hensley holds an Investigators in the Pathogenesis of Infectious Disease Awards from the Burroughs Wellcome Fund.
Author Declarations
All relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.
Yes
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
All data are in the manuscript. Raw data can be obtained from senior author after publication in peer reviewed journal.
